Latham advises PSP Investments in its reinvestment in Cerba HealthCare

Cerba HealthCare, leading player in medical diagnosis, together with Partners Group, and PSP Investments have entered into exclusive discussions with EQT Private Equity to enable the Company to pursue its long-term innovation services strategy and enhance services for patients and the medical community. 

Cerba HealthCare, headquartered in France and firmly established in Europe and Africa through its historical routine and specialty biology expertise, also operates globally through its clinical trials business unit for the validation of new compounds and vaccines. It stands as a unique group in the diagnosis market, covering the needs for diagnostic tools and expertise for patients, physicians, hospitals and the pharmaceutical industry. 

With this new partnership, Cerba HealthCare reinforces its capital structure with its existing shareholders -more than 400 long-time biologists and managers- and its long-term partner, PSP Investments, to sustain the Group’s development strategy and current transformation. The transaction represents an exit for Partners Group after its initial investment in 2017. 

Following the completion of the deal, which is subject to administrative notifications and regulatory approvals, EQT Private Equity and PSP Investments will work with Cerba HealthCare's management team, led by CEO Catherine Courboillet, to support the numerous growth opportunities of the business. These include the continuation of the Company's highly successful M&A strategy on a global scale, as well as the acceleration of organic growth and development in other segments.

Latham advises PSP Investments in this transaction with a Paris corporate team led by partner Gaëtan Gianasso, with Michael Colle. Partner Xavier Renard advises on tax aspects, partner Adrien Giraud with Wenceslas Chelini on antitrust and partner Matthias Rubner with Celia Gallo on labor law aspects.